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Abstract 
Background: Women living in rural and under-resourced Appalachian Kentucky may 
experience delays in receiving cancer treatment yet such delays have not been 
systematically evaluated. In this analysis, we hypothesize that women diagnosed with 
breast cancer who live in Appalachian Kentucky would be more likely to have a 
treatment delay compared to those living in other Kentucky regions and adjusting for 
individual measures of socioeconomic status.  
Methods: In this cohort study, women included in the Kentucky Cancer Registry with a 
diagnosis of an incident, primary breast cancer in the prior 12 months were interviewed 
by phone (n=1,245; response rate 26.9%). Cox proportional hazards regression analysis 
was used to estimate rates of any treatment initiation and rates of specific types of first 
treatment of Appalachian residence relative to non-Appalachian residence after a breast 
cancer diagnosis.  
Results: In contrast to our hypothesis, Appalachian women received any first cancer 
treatment sooner than non-Appalachian women after adjusting for age and stage (adjusted 
hazard ratio= 1.14; p=0.04). When additionally adjusting for income and health 
insurance, this association was no longer statistically significant (adjusted hazard 
ratio=1.11; p=0.14). Among women diagnosed at an earlier stage (n=899), Appalachian 
residents received first treatment (primarily surgery) sooner than Non-Appalachian 
women (p=0.05) and among those diagnosed at a later stage (n=346), Appalachian 
residence received radiation sooner than non-Appalachian residents (p=0.06). There were 
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also no statistical differences in receipt of chemotherapy or hormone therapy between 
Appalachian and non-Appalachians. 
Conclusion: Our results indicate for the first time no disparity related to breast cancer 
diagnosis-treatment intervals in Appalachian Kentucky as compared with the rest of the 
state.  
Key words: Appalachia, low socio-economic status, cancer, treatment 
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Introduction 
The breast cancer mortality rate in the United State as a whole has decreased 
significantly in recent years, but this rate declined more slowly in Appalachian regions.
1
 
In Kentucky, the age-adjusted death rate due to female breast cancer of Appalachians was 
virtually the same as that of non-Appalachian residents during the period from 1995 
through 2007.
2
 Unfortunately, this rate has become higher in Appalachian Kentucky 
relative to the other regions within the state in the five recent years, and significantly 
higher in 2012 at respective rates of 26.4 per 100,000 (22.8 – 30.3) versus 20.4 per 
100,000 (18.4 – 22.6).
2
 Nevertheless, little research has explored what causes this 
disproportionately decreasing trend as well as the disparity related to the breast cancer 
mortality rate.
3
 Most breast cancer death is assumed to be the result of delays in cancer 
detection and treatment.
4-7
 Several studies indicated an association of lower socio-
economic status and increased delays in breast cancer treatment.
8-11
 Inherent given 
geographic isolation and distinguished mountain culture, Appalachian women may suffer 
longer delays in breast cancer treatment. However, this potential disparity has not yet 
been studied thoroughly because cancer survivorship data for the Appalachian region 
from the Surveillance, Epidemiology, and End Results (SEER) program did not become 
available until recent years, and information related to individual socio-economic status 
has not been collected from the cancer registries.
12
  
To examine the disparity in treatment delays in Appalachian women, we created 
the Directed Acyclic Graphs (DAG) to hypothesize a mechanism by which Appalachian 
women may be associated with increased delays in beginning treatment for breast cancer 
(Figure 1). Appalachian residents are characterized by lower socio-economic status, 
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lower income, lower educational attainments, and higher unemployment rates than 
residents of other regions within the state.
13,14
 Such vulnerable status is likely to result in 
lower health insurance coverage, later cancer stage at diagnosis, and more comorbid 
conditions due to unfavorable health behaviors in Appalachian regions.
15
 These 
consequences may either/both directly cause delays in cancer treatment or/and indirectly 
affect the delays through cancer treatment options, which are determined by stage at 
diagnosis and comorbid conditions. 
In this report, we investigated the association between Appalachian region and 
delays in receipt of breast cancer treatment among women included in the Kentucky 
Cancer Registry and agreeing to phone surveys within 12 months of their cancer 
diagnosis. We hypothesized that Appalachian women with breast cancer would 
experience longer delays in treatment initiation as compared with non-Appalachian 
women, after adjusting for differences in socio-demographic characteristics and cancer 
stage and treatment between the two study groups. Specifically, our research questions 
are whether and how Appalachian women with breast cancer are associated with 
increased delays in receipt of cancer treatment relative to non-Appalachian women. 
Methods 
Study Participants 
Women aged 18 to 79 who were diagnosed as an incident and primary case of 
cancer (excluding squamous cell skin cancer) from December 2009 to August 2014 were 
reported to the Kentucky Cancer Registry (KCR). After verifying pathology reports and 
checking with the patients’ physician if the patients were approachable, eligible women 
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were sent a letter to participate in the study, enclosed with card stamped and addressed to 
KCR staff. KCR staff followed up with women who did not return the card to ask if they 
would be willing to talk with University of Kentucky researchers about study 
participation. A total of 4628 women with breast cancer were identified by KCR staff as 
eligible based on age, incident and primary breast cancer diagnosis confirmed by biopsy, 
and diagnosed with in the past 12 months. Of those 4628 women, 2214 agreed to allow 
researchers contact (47.8%) and 1245 completed a phone interview (26.9% of all eligible 
and 56.2% of those consenting to researcher contact). The phone interview included 
questions regarding socio-demographic characteristics, lifestyle factors, and self-reported 
comorbidity.  
Measures 
The cancer treatment outcomes investigated included whether the case received 
treatment, if so the cancer treatment type, and the date of first treatment by type. These 
data were available from the Kentucky Cancer Registry and abstracted by KCR staff 
from case medical records. These data were used to create indicator variables describing 
receipt of any treatment, and specific types of treatment included as dichotomous 
variables for each treatment option: surgery, chemotherapy, radiation, and hormone 
therapy. Additionally, the date of first treatment by type was obtained and used to 
determine time to first treatment by type. The following time to treatment variables were 
created in which the date of diagnosis was used as the benchmark for time to first 
treatment (where time to first is calculated as date of first treatment – date of diagnosis): 
first treatment independent of treatment type, time to first surgery, first chemotherapy, 
first radiation and first hormone therapy. Time to treatment by type was also calculated 
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and included those receiving a specific treatment yet this treatment type was not 
necessarily their first. Since the physicians’ recommendation for treatment types is based 
on tumor characteristics and patient’s health condition, such as chemotherapy is usually 
not part of first course treatment for earlier stages of cancer,
16
 the cases who were 
recommended the treatment but had not received treatment (by type) by KCR medical 
abstraction (between 9 – 12 months following a diagnosis) were considered as censored 
for survival analyses. Lastly, because we could not determine a physicians’ 
recommendation for treatment relative to treatment received we explored days to first 
treatment (and by treatment type) among those who received the specific type of 
treatment. The underlying assumption is that those who received treatment needed that 
treatment.  
Living in Appalachian Kentucky was the primary exposure of interest. Data to 
characterize this status was available from KCR was identified based on Kentucky county 
of residence. Breast cancer cases were grouped as Appalachian and non-Appalachian 
regions for this cohort analysis. 
As described in Figure 1, covariates of potential interest which may impact delays 
in cancer treatment included women’s self-report were their (1) family’s monthly income 
including assistance from their families (grouped into six categories: less than $1,000; 
$1,000 to $1,999; $2,000 to 2,999; $3,000 - $3,999; $4,000 - $4,999; and more than 
$5,000), (2) highest educational attainment (groups into five categories: less than high 
school, some high school or General Educational Development (GED), college or 
vocational certificates, bachelor degree, and post graduate degree), (3) current and 
previous smoking status (categorized as never, former and current smokers), (4) current 
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marital status (dichotomized as married versus unmarried), and (5) health insurance 
coverage (grouped as uninsured including self-pay or no insurance, Medicare, Medicaid 
or government plans, and private insurance). Finally, to measure (6) comorbid conditions, 
women were asked whether a doctor had ever told them they had any of the following 
conditions: a) asthma, chronic bronchitis, emphysema, or chronic obstructive pulmonary 
disease, b) high blood pressure or hypertension or high cholesterol, c) heart disease or a 
heart attack, d) hepatitis or cirrhosis, e) diabetes, metabolic syndrome or were insulin 
resistant, f) irritable bowel syndrome or diverticulitis or diverticulosis, g) fibromyalgia or 
chronic fatigue syndrome, and h) stroke or a transient ischemic attack (TIA). Response 
options for each condition were yes or no. Physical conditions were summed to create an 
ordinal variable indicating the number of conditions the woman has had (frequencies 
ranged from 0 to 8 conditions at cancer diagnosis). Two additional predictors of cancer 
survival and treatment available from KCR were (7) age at diagnosis (in years), and (8) 
stage at cancer diagnosis (defined as carcinoma in situ (=0), localized (=1), regional with 
invasion in the immediate area of the tumor site (=2), regional with cancer invasion 
beyond the immediate region of the tumor (=3); and distant; cancer invasion to another 
site (=4)). 
Statistical Analysis 
As described in Figure 1, socio-demographic factors may be correlated with 
Appalachian region. To determine these associations the Chi-square test for the 
proportions of categorical variables or a two-sample t- test for the means of continuous 
variables were calculated by Appalachian versus non-Appalachian region  (Table 1).  
Besides, assessments of collinearity between the covariates indicated that there was no 
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significant effect of multicollinearity as the Spearman correlation coefficients of the 
factors were less than 0.70, and the variance inflation factors were all less than 10, 
similarly (Appendix).  
The primary research question evaluated was the association between 
Appalachian region and receipt of cancer treatment measures as a dichotomous variable, 
as continuous measures of time to treatment among those treated, and as time to 
treatment using survival analyses modeling. Three statistical methods were used to 
examine the effect of Appalachian residence on cancer treatment among women recently 
diagnosed with breast cancer. When cancer treatment was measured simply as receipt of 
any treatment and by specific treatment type, unadjusted and adjusted logistic regression 
models were used to estimate the odds of treatment among Appalachian and non-
Appalachian residence (see Table 2 for results). When days to cancer treatment among 
those receiving treatment was used to characterize cancer treatment received, unadjusted 
and adjusted linear regression models were used to estimate days to treatment among 
those in Appalachian versus non-Appalachian regions (see Table 3 for results). And 
finally, when both the proportion treated and time to first treatment were used together to 
estimate treatment rate ratios, Cox Proportional Hazards Regression was employed for 
estimating rates of treatment initiation following a cancer diagnosis (see Table 4 for 
results).  These analyses were repeated by type of cancer treatment and within stage of 
cancer diagnosis (dichotomized as earlier (stage 0-2) and later (stage 3-4) stage (see 
Table 5 for results). Kaplan Meier Curves were produced and presented in figure 2 by 
Appalachian versus non-Appalachian region and time to treatment by type. Finally, 
diagnostic tests for the final Cox model were provided in the Appendix. Cumulative sums 
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of martingale residual plots indicated none of the covariates violated the proportional 
hazard assumption and functional form. In terms of influential observations that were 
tested by changes of beta coefficient of Appalachian variable in the model and by 
changes in over model likelihood, we checked information of the observations, and 
contrasted the uncorrected models and the models corrected for influential observations. 
As the information was reasonable, and the differences in uncorrected and corrected 
models were minor, we reported the uncorrected models for simplicity.  
For each model, the following three sets of statistical adjustments to address 
covariates were employed (1) the crude estimates to examine the total effect of 
Appalachian residence on treatment outcomes, (2) adjustment for age at diagnosis, cancer 
stage, and other treatment types which are essential clinical factors for a consideration of 
treatment plans,
16,17
 and (3) the final and more conservative additional adjustment of 
family income and health insurance. Statistical Analysis Software, SAS version 9.3 (SAS 
Institute; Cary North Carolina) was used for all modeling and statistical analyses. 
Results 
Among the 1,245 women participating in this study, 334 women lived in the 
Appalachian region (26.83%). Relative to women living in non-Appalachian Kentucky, 
those living in Appalachia (see Table 1) were more likely to be White (p=.0003), to have 
lower income (p<.0001), to receive less education (p<.0001), to be current smokers 
(p=.01), to have other than private health insurance (p<.0001), to have more comorbid 
conditions (p=.001) and to be diagnosed at a later stage with breast cancer (p=.007). No 
regional differences were noted in age at diagnosis and current marital status.  
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As represented in Table 2, 1,240 out of 1,245 women with breast cancer received 
treatment (99.6%). Similarly the majority (98.4%; 1,225/1,245) received surgery and for 
92.5% surgery was the first cancer treatment. No differences by Appalachian region were 
noted in receipt of any treatment or receipt of surgery specifically in unadjusted or 
adjustment logistic regression models. The proportions of women receiving 
chemotherapy, radiation or hormone therapy as the first course of treatment were 
significantly lower in Appalachian women in comparison to these of non-Appalachian 
women regardless of control for age, stage and treatment types in logistic regression 
models. When we adjusted for these factors along with individual income and health 
insurance only odds ratio for receipt of radiation remained statistical significant but not 
for receipt of chemotherapy or hormone therapy.  
The results of the analyses addressing days to treatment among those receiving 
treatment by Appalachian residence are provided in Table 3. Number of days between 
diagnosis date and first treatment date as our outcome of interest were statistically 
different between the Appalachian and non-Appalachian groups (the means were 19.87 
versus 23.10, with a p-value for a t-test of 0.02 when adjusting for age, and stage yet 
when additionally (and more conservatively) adjusting for income and health insurance, 
regional differences were no longer significant. Briefly, women living in Appalachian 
Kentucky had fewer days to first treatment (p<.05) than did women living in Non-
Appalachian Kentucky. This pattern was observed for days to first treatment, surgery, 
radiation, and hormone therapy when considered adjusted models. No regional 
differences in time to treatment were observed for chemotherapy between the two study 
groups.  
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Figure 2 illustrates the Kaplan-Meier curves for time to treatment by Appalachian 
region. Since p values of the Log Rank test for the time to any first treatment and time to 
first surgery were less than a five percent significance level, we have strong evidence to 
conclude that the curves are different when comparing Appalachian breast cancer women 
versus non-Appalachian breast cancer women, not taking into account any other covariate 
information. Yet we failed to reject the null hypothesis that the curves for the time to first 
chemotherapy or the time to first radiation or the time to hormone therapy were the same 
for the two groups at all points in time.  
The results of the Cox proportional hazards model with and without covariate 
adjustments are provided in Table 4; time to median treatment probability by 
Appalachian region were provided as well as the hazard ratios for cancer treatment by 
type. The unadjusted hazard ratio for any treatment received of 1.17 [95% CI: (1.04 – 
1.33)] indicates that women in Appalachian Kentucky were 17% more likely to receive 
any cancer treatment earlier than women living in Non-Appalachian regions. While this 
association remained significant when adjusting for age and stage at diagnosis (HR= 
1.14; 95% CI=1.01 – 1.30), the more conservative adjustment for age, stage at diagnosis, 
income and health insurance resulted in a HR of 1.11 [95% CI: (0.97 – 1.28)] was no 
longer significant. This finding does suggest that the effect of Appalachian residence on 
time to any first cancer treatment may be mediated by income or insurance and not 
simply residence. Appalachian women appeared be more likely to receive surgery and 
radiation earlier than women living in Non-Appalachian regions (note differences in 
findings by adjustments in models). 
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When these analyses were repeated by stage at cancer diagnosis (Table 5) similar 
findings were observed for Appalachian residence being more likely to receive any and 
specifically surgery sooner than Non-Appalachian residents among those diagnosed at an 
earlier stage (0-2). No difference in treatment by Appalachian were noted among women 
diagnosed at later stage.  
Discussion 
In this cohort analysis, Appalachian women diagnosed with breast cancer tended 
to receive any first cancer treatment or first surgery slightly sooner than those in non-
Appalachian regions. By adjusting for individual income, health insurance, other types of 
treatment, age and cancer stage at diagnosis the differences in rates of treatment initiation 
were not statistically significant. The findings did not concur with our hypothesis that 
women living in underserved Appalachian region might suffer delays in breast cancer 
treatment. Since this is the first study to explore time to first cancer treatment by type 
among women diagnosed with breast cancer in Appalachia compared to those living in 
the rest of Kentucky, we are thus not able to compare our results with others. The results 
might be partially explained by the higher proportion of the Appalachian women who 
were diagnosed and treated on the same day compared to that of non-Appalachian 
women (20.42% versus 16.65%, a p value for the Chi-square test of 0.12). Moreover, 
while the proportion of patients at stage 4 was higher in the Appalachian group compared 
to the non-Appalachian group, the patients at stage 4 were likely to initiate treatment 
sooner. By contrast, the proportion of patients at stage 0 was lower in Appalachian 
Kentucky, whereas the women at stage 0 were likely to start treatment later. Women with 
monthly income from $4,000 to $4,999, which was observed less often in Appalachian 
 13 
group tended to have a longer delay in cancer treatment. Yet the patients with a medium 
level of income, who may have underlying factors such as current employment, would 
take a longer time to arrange for a treatment.  
Our results indicate a four-day difference in the mean or median number of days 
from diagnosis to any first treatment and a five-day difference in the mean or median 
number of days from diagnosis to first surgery between the two study groups. A recent 
study reported a treatment delay of more than 60 days to be associated with an increased 
risk of breast cancer-related death among patients at late stages.
10
 We might also over 
adjust when controlling individual’s insurance and income along with essential clinical 
factors that affect the treatment options. However, the findings might be good news if we 
can say that clinicians recognize the burden of distance of travel burden and get those 
from greater distance into treatment sooner. 
In the Cox regression models, due to differences in treatment plans recommended 
for the patients we considered censors as cases who were recommended a treatment type 
but had not received that treatment. It is reasonable to exclude those who were not 
recommended for a treatment when rates of receiving specific types of treatment were 
estimated. For instance, 98% (54/55) of the cases at stage 0, and 60% of the cases at stage 
1 were not recommended for chemotherapy, and were thus excluded in the analysis of 
time to first chemotherapy, whereas only 15% of the cases at stage 3 were not 
recommended for chemotherapy. However, analyses also suggested that Appalachian 
women were less likely to be recommended for a chemotherapy or radiation or hormone 
therapy as compared with non-Appalachian women. Without controlling for potential 
confounders such as cancer stage, radiation was recommended for 63% of non-
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Appalachian women while it was recommended for only 54% of Appalachian women 
(p=.007). Hormone therapy was recommended for 73% of non-Appalachian women 
versus for 69% of Appalachians (p=.17). Chemotherapy was recommended for 55% of 
non-Appalachian women versus for 52% of Appalachians (p=.38). The results imply that 
our exclusion of patients who were not recommended for a specific treatment type might 
overshadow treatment-related disparities in the Appalachian regions. They also raise 
another important question for further study, whether non-clinical patient factors, 
including living in Appalachian regions influence doctors’ recommendation for treatment 
plans in our study. Some previous studies suggested that patient’s circumstances related 
to health insurance, travel difficulties or income play a role in medical oncologist 
decision-making for cancer treatment recommendations.
18-22
 
Our study has several strengths. This is the first longitudinal study design to 
compare time from diagnosis to first treatment among Appalachian women diagnosed 
with breast cancer versus those in the rest of the state. This study also considers the 
effects of numerous potential predictors on diagnosis-treatment time intervals by various 
statistical models. In addition, missing data and recall bias are very limited in our study. 
There is also little to no chance of differential misclassification of outcome and exposure 
as the study subjects were not reporting either Appalachian status or date of treatment by 
type. Thus only non-differential misclassification that introduces a bias toward the null 
might occur. 
However, our study contains some limitations. First and foremost, time to cancer 
treatment that was determined from date of confirmed diagnosis to date of treatment only 
reflects treatment delays among the women who present at health facilities for a cancer 
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diagnosis, but does not measure the delays among those who are unable to access health 
services to be diagnosed. This may lead to underestimation of actual delays in cancer 
treatment. Comprehensive assessments of delays, including primary delays (duration 
between onsets of the symptoms and contacting health professionals), secondary delays 
(time interval of presenting at a health facility and getting a confirmed diagnosis), and 
these tertiary delays can be used for strengthening the results. Additional measures 
known to influence treatment delays, such as physician-related delays before and after 
diagnosis may also have been beneficial to gather and include in our regression model. 
Another limitation to our study is non-response bias that may be present, and 
questionable generalizability of the findings due to a low response rate (22.3%). 
However, there was no statistical difference in response rates between Appalachian 
women (24.6%) and non-Appalachian women (23.0%), which might mitigate the bias. 
Furthermore, extension of the study locations to other cancer registries in Appalachian 
areas to increase generalizability and further assess covariate effects such as women’s 
educational attainment, employment, or income, may be helpful in assessing the impact 
of Appalachian residence on time to first cancer treatment.  
In conclusion, our study contributes to the literature with regards to duration 
between diagnosis and treatment dates among women with breast cancer in Appalachian 
Kentucky in comparison to the rest within the state. While the study results did not reveal 
the disparity related to delays in initiating breast cancer treatment in Appalachian women 
as compared to non-Appalachian women in Kentucky, efforts to improve the breast 
cancer screening programs in order to reduce late breast cancer diagnosis for Appalachian 
women should continue to be.  
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Table 1: Demographic Profile of Women with Breast Cancer by Appalachian Residence, 2009 - 2014 
Variables All women Appalachian Non-Appalachian P value  (χ
2
 or t test) 
Age at Diagnosis  N=1,245 N=334 N=911 p= 0.12 (t df=1243=-1.55) 
Mean (SD) 56.61 (9.90) 57.33 (9.91) 56.35 (9.89)  
Race N=1,240 N=333 N=907 p<0.0003 (χ
2
df=1=13.19) 
White 1,174 (94.68%) 328 (98.50%) 846 (93.27%)  
Non-White 66 (5.32%) 5 (1.50%) 61 (6.73%)  
Woman’s Monthly Income  N=1,018 N=286 N=732 p<0.0001 (χ
2
df=5=43.55) 
<$1,000 102 (10.02%) 39 (13.64%) 63 (8.61%)  
$1,000 - $1,999 201 (19.74%) 83 (29.02%) 118 (16.12%)  
$2,000 – 2,999 151(14.83%) 48 (16.78%) 103 (14.07%)  
$3,000 - $3,999 140 (13.75%) 30 (10.49%) 110 (15.03%)  
$4,000 - $4,999 112 (11.0%) 31 (10.84%) 81 (11.07%)  
≥$5,000 312 (30.65%) 55 (19.23%) 257 (35.11%)  
Woman’s Educational Attainment N=1,244 N=334 N=910 p<0.0001 (χ
2
df=4=54.88) 
Less than High School 101 (8.12%) 52 (15.57%) 49 (5.38%)  
High School/ GED 403 (32.40%) 123 (36.83%) 280 (30.77%)  
College/Technical 224 (18.01%) 51 (15.27%) 173 (19.01%)  
Bachelor Degree 164 (13.18%) 49 (14.67%) 115 (12.64%)  
Post Graduate Degree 352 (28.30%) 59 (17.66%) 293 (32.20%)  
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Variables All women Appalachian Non-Appalachian P value  (χ
2
 or t test) 
Current Marital Status  N=1,244 N=334 N=910 p=0.55 (χ
2
df=1=0.35) 
Married 848 (68.17%) 232 (69.46%) 616 (67.69%)  
Unmarried 396 (31.83%) 102 (30.54%) 294 (32.31%)  
Woman’s Smoking Status N=1,245 N=334 N=911 p=0.01 (χ
2
df=2=9.00) 
Never smoker 707 (56.79%) 185 (55.39%) 522 (57.30%)  
Current smoker 153 (12.29%) 56 (16.77%) 97 (10.65%)  
Former smoker 385 (30.92%) 93 (27.84%) 292 (32.05%)  
Health Insurance or Plans N=1,245 N=334 N=911 p<0.0001 (χ
2
df=3= 32.99) 
Private insurance 795 (63.86%) 174 (52.10%) 621 (68.17%)  
Medicaid/Military 97 (7.79%) 35 (10.48%) 62 (6.81%)  
Medicare 321 (25.78%) 108 (32.34%) 213 (23.38%)  
Not Insured 32 (2.57%) 17 (5.09%) 15 (1.65%)  
Number of Comorbid Conditions  N=1,241 N=333 N=908 p=0.001 (tdf=527=-3.24) 
Mean (SD) 1.62 (1.24) 1.82 (1.37) 1.55 (1.19)  
Cancer Stage at Diagnosis N=1,245 N=334 N=911 p=0.007 (χ
2
df=4=14.09) 
Stage 0  55 (4.42%) 7 (2.10%)  48 (5.27%)  
Stage 1  826 (66.35%) 227 (67.96%) 599 (65.75%)  
Stage 2  18 (1.45%) 4 (1.20%) 14 (1.54%)  
Stage 3  313 (25.14%) 80 (23.95%) 233 (25.58%)  
Stage 4 33 (2.65%) 16 (4.79%) 17 (1.87%)  
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Table 2: Appalachian Residence and Type of Cancer Treatment Received among Women Diagnosed with Breast Cancer, 2009 
- 2014 
Variables All women  
n (%) 
Appalachian 
n (%) 
Non-Appalachian 
n (%) 
Appalachian versus Non-Appalachian 
Unadjusted 
OR (95% CI) 
Adjusted OR* 
(95% CI) 
Adjusted 
OR** (95%CI) 
Received treatment         
Yes 1,240 (99.60%) 333 (99.70%) 907 (99.56%) 1.47***  
(0.16 – 13.19)  
1.44  
(0.16 – 12.97)  
1.44  
(0.15 – 13.59)  
No 5 (0.40%) 1 (0.30%) 4 (0.44%) 
Received surgery        
Yes 1,225 (98.39%) 326 (97.60%) 899 (98.68%) 0.54  
(0.22 – 1.34)  
1.07  
(0.38 – 2.99)  
1.004  
(0.32 – 3.18)  
No 20 (1.61%) 8 (2.40%) 12 (1.32%) 
First treatment was 
surgery 
       
Yes 1,151 (92.45%) 310 (92.81%) 841 (92.32%) 1.08  
(0.66 - 1.74)  
1.31  
(0.77 – 2.23)  
1.38  
(0.76 – 2.52)  
No 94 (7.55%) 24 (7.19%) 70 (7.68%) 
Received 
chemotherapy  
      
Yes 599 (48.11%) 145 (43.41%) 454 (49.84%) 0.77  
(0.60 – 0.99) 
0.68  
(0.51 – 0.92)  
0.66  
(0.48 – 0.93)  
No 646 (51.89%) 189 (56.59%) 457 (50.16%) 
First treatment was 
chemotherapy  
      
Yes 73 (5.86%) 21 (6.29%) 52 (5.71%) 1.11  0.95  0.84  
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Variables All women  
n (%) 
Appalachian 
n (%) 
Non-Appalachian 
n (%) 
Appalachian versus Non-Appalachian 
Unadjusted 
OR (95% CI) 
Adjusted OR* 
(95% CI) 
Adjusted 
OR** (95%CI) 
No 1,172 (94.14%) 313 (93.71%) 859 (94.29%) (0.66 – 1.87)  (0.53 – 1.72)  (0.42 – 1.70)  
Received radiation        
Yes 691 (55.50%) 156 (46.71%) 535 (58.73%) 0.62  
(0.48 – 0.79)  
0.65  
(0.50 – 0.85)  
0.68  
(0.50 – 0.91)  
No 554 (44.50%) 178 (53.29%) 376 (41.27%) 
First treatment was 
radiation 
      
Yes 2 (0.08%) 0 2 (0.22%) *** *** *** 
No 1,234 (99.12%) 334 (100%) 909 (99.78%) 
Received hormone        
Yes 805 (64.66%) 196 (58.68%) 609 (66.85%) 0.70  
(0.54 – 0.91)  
0.69  
(0.52 – 0.92)  
0.77  
(0.57 – 1.04) 
No 440 (35.34%) 138 (41.32%) 302 (33.15%) 
First treatment was 
hormone  
      
Yes 23 (1.85%) 6 (1.80%) 17 (1.87%) 0.96  
(0.38 – 2.46)  
0.65  
(0.23 – 1.88)  
0.78  
(0.25 – 2.43)  
No 1222 (98.15%) 328 (98.20%) 894 (98.13%) 
*Odds ratios (OR) for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, and other treatment received (except 
for specific treatment as first). 95% confidence intervals (CI) are given in parentheses. 
** ORs for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, other treatment received (except for specific 
treatment as first), income and health insurance. 95% CIs are given in parentheses. 
***Unstable ORs due to the small number of women who received or did not received a treatment.
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Table 3: Appalachian Residence and Time to First Treatment by Type among Women Receiving the Specific Treatment, 2009 
– 2014 
Variables Unadjusted mean days to cancer treatment (SE)  β estimate (95% CI) for Appalachian versus Non-
Appalachian 
All women Appalachian Non-Appalachian Unadjusted Adjusted* Adjusted** 
Days to first 
treatment  
22.23 (0.53) 19.87 (1.02) 23.10 (0.62) -3.23  
(-5.56; -0.89) 
p= 0.007  
-2.79  
(-5.13; -0.45)  
p= 0.02  
-2.18  
(-4.84; 0.49) 
p= 0.11 
Days to first 
surgery  
28.94 (1.05) 24.18 (1.68) 30.67 (1.29) -6.5  
(-11.14; -1.85)  
p= 0.01 
-5.89  
(-10.5;-1.29) 
p=0.01  
-5.39  
(-10.49; -0.29)  
p =0.04  
Days to surgery 
where surgery is 
first treatment  
21.88 (0.55) 19.38 (1.06) 22.80 (0.65) -3.42  
(-5.86; -0.98)  
p= 0.006 
-3.13  
(-5.60;-0.66)  
p= 0.01 
-2.45  
(-5.22; 0.33)  
p= 0.08 
Days to first 
chemotherapy  
62.91 (1.31) 63.69 (2.96) 62.66 (1.45) 1.03  
(-5.00; 7.06) 
p=0.74 
2.83  
(-2.96; 8.62) 
p=0.34 
3.06  
(-3.46; 9.58) 
p=0.36 
Days to 
chemotherapy 
where 
chemotherapy is 
first treatment  
27.00 (1.89) 26.57 (3.22) 27.17 (2.33) -0.60 
(-8.98; 7.77) 
p=0.89 
-3.70 
(-12.55; 5.14) 
p=0.41 
-2.02 
(-13.61; 9.57) 
p=0.73 
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Variables Unadjusted mean days to cancer treatment (SE)  β estimate (95% CI) for Appalachian versus Non-
Appalachian 
All women Appalachian Non-Appalachian Unadjusted Adjusted* Adjusted** 
Days to first 
radiation 
137.92 (3.15) 129.30 (7.31) 140.40 (3.46) -11.14  
(-25.9; 3.62)  
p=0.14 
-8.37  
(-17.82; 1.08) 
p=0.08 
-14.46  
(-25.12; -3.8)  
p =0.01 
Days to hormone 
therapy 
134.84 (3.32) 124.10 (6.50) 138.30 (3.84) -14.23  
(-29.37; 0.92) 
p=0.07 
-7.88  
(-19.84; 4.09) 
p=0.20 
-13.06  
(-26.02; -0.1) 
p=0.048 
Days to hormone 
therapy where 
hormone therapy 
is first treatment 
19.70 (3.53) 12.33 (5.44) 22.29 (4.28) -9.96 
(-26.48; 6.56) 
p=0.22  
8.21 
(-7.98; 24.41) 
p=0.30  
11.69 
(-23.34; 46.71) 
p=0.45  
*SE: Standard error 
* Non-intercept parameter estimates (β) for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, and other 
treatment received (except for specific treatment as first). 95% confidence intervals (CI) are given in parentheses. 
** β estimates for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, other treatment received (except for 
specific treatment as first), income and health insurance. 95% CIs are given in parentheses 
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Table 4: Survival Analyses: Appalachian Residence and First Cancer Treatment among Women with Breast Cancer, 2009 - 
2014 
Outcomes Median Treatment Time* (95% CI) HR (95% CI) for Appalachian versus Non-Appalachian 
Appalachian Non-Appalachian  Unadjusted  Adjusted HR** Adjusted HR*** 
Time to First 
Treatment  
16 (14 – 18)  
N=334  
21 (20 – 22) 
N=911 
1.17 (1.04 – 1.33) 
 p=0.01 
1.14 (1.01 – 1.30) 
 p=0.04 
1.11 (0.97 – 1.28) 
p=0.14 
Time to first 
surgery 
17 (15 – 20) 
N=334 
22 (21 – 23) 
N=911 
1.14 (1.002 – 1.29) 
p=0.046 
1.18 (1.03 – 1.34) 
 p=0.01 
1.14 (0.99 – 1.32) 
p=0.08 
Time to first 
chemotherapy 
60 (52 – 65) 
N=155 
62 (57 – 65) 
N=480 
0.96 (0.79 – 1.15) 
 p=0.64 
0.88 (0.72 – 1.06)  
p=0.17 
0.84 (0.68 – 1.04) 
 p=0.12 
Time to first 
radiation 
110 (86 – 143) 
N=161 
145 (118 – 160) 
N=549 
1.11 (0.93 – 1.33) 
 p=0.26 
1.16 (0.97 – 1.39) 
 p=0.11 
1.33 (1.08 – 1.62) 
p=0.006 
Time to first 
hormone  
103.50 (82 – 136) 
N=206 
126 (114 – 137) 
N=624 
1.02 (0.87 – 1.20) 
p=0.83 
0.97 (0.83 – 1.15) 
p=0.75 
1.07 (0.89 – 1.28) 
p=0.50 
* Time point at which 50% of patients have received first cancer treatment by Kaplan Meijer method 
** Cox proportional hazards regression models: Hazard ratios (HR) for receipt of cancer treatment, controlling for age at diagnosis, 
cancer stage, and other treatment received (except for specific treatment as first). 95% confidence intervals (CI) are given in 
parentheses. 
*** Cox proportional hazards regression models: HRs estimates for receipt of cancer treatment, controlling for age at diagnosis, 
cancer stage, other treatment received (except for specific treatment as first), income and health insurance. 95% CIs are given in 
parentheses. 
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Table 5: Survival Analyses: Appalachian Residence and First Cancer Treatment among Women Recently Diagnosed with 
Breast Cancer, Stratified by Cancer Stage, 2009 - 2014 
Outcomes Median Treatment Time* (95% CI) HR (95% CI) for Appalachian versus Non-Appalachian 
Appalachian Non-Appalachian Unadjusted  Adjusted **  Adjusted ***  
Among women diagnosed with earlier stage breast cancer - Stage 0 – 2 (N=899) 
Time to first 
treatment  
17 (15 – 19) 
N=238 
21 (20 – 23) 
N=661 
1.25 (1.08 – 1.45) 
 p=0.003 
1.23 (1.06 – 1.43) 
 p=0.006 
1.18 (0.999 – 1.39) 
p=0.051 
Time to first 
surgery 
17 (15 – 20) 
N=238 
22 (20 – 23) 
N=661 
1.21 (1.04 – 1.40) 
 p=0.01 
1.22 (1.05 – 1.42)  
p=0.01 
1.18 (0.997 – 1.40) 
p=0.055 
Time to first 
chemotherapy 
68 (60 – 78) 
N=81 
66.5 (62 – 70) 
N=266 
0.93 (0.72 – 1.20) 
 p=0.57 
0.87 (0.66 – 1.13) 
 p=0.29 
0.83 (0.62 – 1.12) 
 p=0.23 
Time to first 
radiation 
85 (70 – 99) 
N=107 
83 (75 – 95) 
N=381 
1.10 (0.88 – 1.36) 
 p=0.41 
1.12 (0.90 – 1.39) 
 p=0.33 
1.21 (0.94 – 1.55) 
p=0.14 
Time to first 
hormone 
85 (70 – 108) 
N=148 
98 (88 – 110) 
N=448 
0.99 (0.82 – 1.20) 
p=0.89 
1.03 (0.85 – 1.24) 
p=0.80 
1.11 (0.90 – 1.38) 
p=0.33 
Among women diagnosed with later stage breast cancer - Stage 3 – 4 (N=346) 
Time to first 
treatment  
15 (12 – 21) 
N=96 
19 (16 – 22) 
N=250 
0.998 (0.79 – 1.27) 
 p=0.99 
0.997 (0.79 – 1.26) 
 p=0.98 
1.03 (0.78 – 1.36) 
 p=0.85 
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Outcomes Median Treatment Time* (95% CI) HR (95% CI) for Appalachian versus Non-Appalachian 
Appalachian Non-Appalachian Unadjusted  Adjusted **  Adjusted ***  
Time to first 
surgery 
16.5 (14 – 24) 
N=96 
23 (19 – 26) 
N=250 
1.08 (0.85 – 1.37)  
p=0.55 
1.10 (0.86 – 1.40) 
 p=0.46 
1.08 (0.81 – 1.44) 
 p=0.60 
Time to first 
chemotherapy 
52 (46 – 61) 
N=74 
55.5 (51 – 59) 
N=214 
0.96 (0.73 – 1.26) 
 p=0.78 
0.93 (0.71 – 1.23) 
 p=0.61 
0.92 (0.67 – 1.25)  
p=0.58 
Time to first 
radiation 
188 (146 – 207) 
N=54 
212 (203 – 220) 
N=168 
1.15 (0.84 – 1.57) 
 p=0.39 
1.05 (0.76 – 1.44) 
 p=0.78 
1.42 (0.99 – 2.05) 
 p=0.06 
Time to first 
hormone 
183 (128 – 209) 
N=58 
183.5 (178 – 202) 
N=176 
1.08 (0.80 – 1.46) 
 p=0.62 
0.89 (0.65 – 1.22) 
 p=0.47 
0.98 (0.67 – 1.43) 
 p=0.92 
* Time point at which 50% of patients have received first cancer treatment by Kaplan Meijer method 
** Cox proportional hazards regression models: Hazard ratios (HR) for receipt of cancer treatment, controlling for age at diagnosis, 
and other treatment received (except for specific treatment as first). 95% confidence intervals (CI) are given in parentheses. 
*** Cox proportional hazards regression models: HRs estimates for receipt of cancer treatment, controlling for age at diagnosis, other 
treatment received (except for specific treatment as first), income and health insurance. 95% CIs are given in parentheses 
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Figure 1: Directed Acyclic Graph (DAG) depicting a hypothesized mechanism for association of Appalachian women and 
delays in receipt of cancer treatment - Created with the online Dagitty at: http://www.dagitty.net/dags.html# 
 
Minimal sufficient adjustment sets containing age at diagnosis for estimating the direct effect of Appalachian women on 
delays in receipt of cancer treatment: stage at diagnosis, socio-economic status and health insurance or plans
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Figure 2: Kaplan Meijer Curves 
Figure 2a. Time to First Breast Cancer Treatment  
 
 
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 6.7424 1 0.0094 
Wilcoxon 11.6179 1 0.0007 
-2Log(LR) 6.4775 1 0.0109 
 
 
 
 
 
 
 31 
Figure 2b. Time to First Surgery 
 
 
 
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 4.2632 1 0.0389 
Wilcoxon 11.2151 1 0.0008 
-2Log(LR) 1.0371 1 0.3085 
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Figure 2c. Time to First Chemotherapy 
 
 
 
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 0.2283 1 0.6328 
Wilcoxon 0.0068 1 0.9343 
-2Log(LR) 0.0044 1 0.9473 
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Figure 2d. Time to First Radiation Therapy 
 
 
 
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 1.2903 1 0.256 
Wilcoxon 3.6693 1 0.0554 
-2Log(LR) 0.1576 1 0.6914 
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Figure 2e. Time to First Hormone Therapy 
 
 
 
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 0.0443 1 0.8333 
Wilcoxon 2.7808 1 0.0954 
-2Log(LR) 0.0003 1 0.9868 
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Appendix 
Table 6: Full Cox proportional hazards regression models for time to any type of 
treatment 
Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
Appalachian Region:   
Appalachian  
Non-Appalachian 
p=0.01 
1.17 (1.04 – 1.33) 
Reference 
p=0.04 
1.14 (1.01 – 1.30) 
Reference 
p=0.14 
1.11 (0.97 – 1.28) 
Reference 
Age at Diagnosis: p=0.01 
1.01 (1.002–1.01) 
p=0.02 
1.01 (1.001–1.01) 
p=0.20 
1.01 (0.99 – 1.01) 
Stage at Diagnosis: 
Stage 0 
Stage 1 
Stage 2 and Stage 3 
Stage 4  
p=0.07 
0.57 (0.37 – 0.88) 
0.76 (0.54 – 1.08) 
0.74 (0.52 – 1.06) 
Reference 
p=0.14 
0.61 (0.39 – 0.94) 
0.79 (0.55 – 1.12) 
0.77 (0.53 – 1.10) 
Reference 
p=0.26 
0.61 (0.37 – 1.01) 
0.80 (0.54 – 1.18) 
0.79 (0.52 – 1.17) 
Reference 
Monthly Income: 
<$1,000 
$1,000 - $1,999 
$2,000 – 2,999 
$3,000 - $3,999 
$4,000 - $4,999 
≥$5,000 
p=0.04 
Reference 
1.46 (1.15 – 1.86) 
1.33 (1.03 – 1.71) 
1.35 (1.05 – 1.75) 
1.14 (0.87 – 1.50) 
1.24 (0.99 – 1.55) 
 p=0.09 
Reference 
1.40 (1.09 – 1.79) 
1.32 (1.01 – 1.73) 
1.37 (1.04 – 1.80) 
1.13 (0.85 – 1.51) 
1.28 (1.00 – 1.64) 
Health Insurance: 
Uninsured 
Medicaid 
Medicare 
Private insurance 
p=0.11 
1.15 (0.81 – 1.64) 
0.87 (0.70 – 1.07) 
1.12 (0.98 – 1.27) 
Reference 
 p=0.75 
0.94 (0.61 – 1.45) 
0.93 (0.73 – 1.20) 
1.07 (0.89 – 1.27) 
Reference 
95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses 
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis and stage at diagnosis 
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, stage at diagnosis, family’s monthly income and health insurance 
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Table 7: Full Cox proportional hazards regression model for time to first surgery 
Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
Appalachian Region:   
Appalachian  
Non-Appalachian 
p=0.046 
1.14 (1.002–1.29) 
Reference 
p=0.01 
1.18 (1.03 – 1.34) 
Reference 
p=0.08 
1.14 (0.99 – 1.32) 
Reference 
Age at Diagnosis: p<0.001 
 1.02 (1.01–1.02) 
p<0.0001 
1.01 (1.01 – 1.02) 
p=0.01 
1.01 (1.002–1.02) 
Stage at Diagnosis: 
Stage 0 
Stage 1 
Stage 2 and Stage 3 
Stage 4  
p<0.0001 
2.26 (1.40 – 3.65) 
2.60 (1.74 – 3.90) 
2.01 (1.33 – 3.03) 
Reference 
p<0.0001 
2.38 (1.46 – 3.87) 
2.58 (1.71 – 3.87) 
2.01 (1.33 – 3.04) 
Reference 
p<0.0001 
2.14 (1.25 – 3.65) 
2.31 (1.50 – 3.55) 
1.81 (1.17 – 2.81) 
Reference 
Monthly Income: 
<$1,000 
$1,000 - $1,999 
$2,000 – 2,999 
$3,000 - $3,999 
$4,000 - $4,999 
≥$5,000 
p=0.17 
Reference 
1.34 (1.05 – 1.71) 
1.23 (0.95 – 1.59) 
1.28 (0.99 – 1.66) 
1.09 (0.83 – 1.43) 
1.25 (0.99 – 1.58) 
 
p=0.41 
Reference 
1.22 (0.95 – 1.56) 
1.19 (0.90 – 1.56) 
1.19 (0.90 – 1.57) 
1.02 (0.76 – 1.36) 
1.21 (0.94 – 1.55) 
Health Insurance: 
Uninsured 
Medicaid 
Medicare 
Private insurance 
p=0.0007 
1.03 (0.72 – 1.48) 
0.79 (0.63 – 0.98) 
1.22 (1.08 – 1.40) 
Reference 
 
p=0.09 
1.23 (0.80 – 1.87) 
0.80 (0.62 – 1.03) 
1.10 (0.92 – 1.32) 
Reference 
Chemotherapy: 
Yes 
No 
p=0.002 
0.84 (0.75 – 0.94) 
Reference 
p=0.54 
0.96 (0.84 – 1.09) 
Reference 
p=0.93 
0.99 (0.86 – 1.15) 
Reference 
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Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
Radiation: 
Yes 
No 
p=0.005 
1.18 (1.05 – 1.32) 
Reference 
p=0.005 
1.18 (1.05 – 1.33) 
Reference 
p=0.006 
1.20 (1.05 – 1.37) 
Reference 
Hormone Therapy: 
Yes 
No 
p=0.10 
1.11 (0.98 – 1.25) 
Reference 
p=0.22 
1.08 (0.95 – 1.22) 
Reference 
p=0.54 
1.04 (0.91 – 1.20) 
Reference 
95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses 
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, other types of treatment and stage at diagnosis 
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and 
health insurance 
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Table 8: Full Cox proportional hazards regression models for time to first 
chemotherapy 
Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR**  
(95% CI)  
Appalachian Region:   
Appalachian  
Non-Appalachian 
p=0.64 
0.96 (0.79 – 1.15) 
Reference 
p=0.17 
0.88 (0.72 – 1.06) 
Reference 
p=0.12 
0.84 (0.68 – 1.04) 
Reference 
Age at Diagnosis: p<0.0001 
0.98 (0.97 – 0.99) 
p<0.0001 
0.98 (0.97 – 0.99) 
p=0.0008 
0.98 (0.97–0.99) 
Stage at Diagnosis: 
Stage 0 
Stage 1 
Stage 2 and Stage 3 
Stage 4  
p<0.0001 
1.63 (0.22–12.15) 
0.32 (0.21 – 0.50) 
0.47 (0.30 – 0.72) 
Reference 
p<0.0001 
2.39 (0.32–17.94) 
0.37 (0.24 – 0.58) 
0.54 (0.35 – 0.86) 
Reference 
p<0.0001 
2.61 (0.34–19.94) 
0.41 (0.25 – 0.67) 
0.64 (0.39 – 1.05) 
Reference 
Monthly Income: 
<$1,000 
$1,000 - $1,999 
$2,000 – 2,999 
$3,000 - $3,999 
$4,000 - $4,999 
≥$5,000 
p=0.09 
Reference 
1.65 (1.16 – 2.33) 
1.47 (1.01 – 2.15) 
1.28 (0.88 – 1.85) 
1.30 (0.90 – 1.88) 
1.49 (1.07 – 2.06) 
 
 
p=0.007 
Reference 
2.08 (1.44 – 3.01) 
1.58 (1.06 – 2.37) 
1.44 (0.97 – 2.13) 
1.53 (1.03 – 2.27) 
1.56 (1.09 – 2.25) 
Health Insurance: 
Uninsured 
Medicaid 
Medicare 
Private insurance 
p=0.0009 
1.02 (0.65 – 1.60) 
0.94 (0.71 – 1.24) 
0.65 (0.53 – 0.80) 
Reference 
 
p=0.20 
0.80 (0.47 – 1.35) 
0.93 (0.66 – 1.31) 
0.75 (0.57 – 0.98) 
Reference 
Surgery: 
Yes 
p<0.0001 
0.20 (0.11 – 0.38) 
p<0.0001 
0.27 (0.14 – 0.52)  
p=0.0008 
0.30 (0.15 – 0.61) 
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Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR**  
(95% CI)  
No Reference Reference Reference 
Radiation: 
Yes 
No 
p=0.15 
1.13 (0.96 – 1.33) 
Reference 
p=0.07 
1.17 (0.99 – 1.38) 
Reference 
p=0.32 
1.10 (0.91 – 1.33) 
Reference 
Hormone Therapy: 
Yes 
No 
p<0.0001 
0.69 (0.59 – 0.82) 
Reference 
p<0.0001 
0.67 (0.56 – 0.79) 
Reference 
p<0.0001 
0.61 (0.50 – 0.74) 
Reference 
95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses 
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, other types of treatment and stage at diagnosis 
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and 
health insurance 
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Table 9: Full Cox proportional hazards regression models for time to first radiation 
Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
Appalachian Region:   
Appalachian  
Non-Appalachian 
p=0.26 
1.11 (0.93 – 1.33) 
Reference 
p=0.11 
1.16 (0.97 – 1.39) 
Reference 
p=0.006 
1.33 (1.08 – 1.62) 
Reference 
Age at Diagnosis: p=0.001 
1.01 (1.01 – 1.02) 
p=0.28 
0.99 (0.99–1.004) 
p=0.69 
0.99 (0.99–1.01) 
Stage at Diagnosis: 
Stage 0 
Stage 1 
Stage 2 and Stage 3 
Stage 4  
p<0.0001 
1.11 (0.57 – 2.18) 
0.98 (0.57 – 1.66) 
0.41 (0.24 – 0.71) 
Reference 
p<0.0001 
0.65 (0.33 – 1.29) 
0.94 (0.55 – 1.61) 
0.55 (0.32 – 0.94) 
Reference 
p<0.0001 
0.90 (0.44–1.88) 
1.02 (0.59 – 1.77) 
0.60 (0.34 – 1.06) 
Reference 
Monthly Income: 
<$1,000 
$1,000 - $1,999 
$2,000 – 2,999 
$3,000 - $3,999 
$4,000 - $4,999 
≥$5,000 
p=0.04 
Reference 
1.40 (0.99 – 1.98) 
1.71 (1.18 – 2.47) 
1.39 (0.97 – 2.00) 
1.30 (0.89 – 1.90) 
1.61 (1.17 – 2.22) 
 
p=0.17 
Reference 
1.03 (0.72 – 1.48) 
1.10 (0.73 – 1.64) 
0.74 (0.50 – 1.11) 
0.89 (0.59 – 1.36) 
1.02 (0.71 – 1.47) 
Health Insurance: 
Uninsured 
Medicaid 
Medicare 
Private insurance 
p=0.004 
0.97 (0.60 – 1.57) 
0.58 (0.43 – 0.78) 
0.91 (0.76 – 1.09) 
Reference 
 
p<0.0001 
0.86 (0.48 – 1.53) 
0.43 (0.30 – 0.62) 
0.59 (0.46 – 0.76) 
Reference 
Surgery: 
Yes 
No 
p=0.18 
3.86 (0.54–27.54) 
Reference 
p=0.01 
11.7 (1.63–83.91) 
Reference 
p=0.02 
10.92 (1.48–80.67) 
Reference 
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Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
Chemotherapy: 
Yes 
No 
p<0.0001 
0.26 (0.22 – 0.31) 
Reference 
p<0.0001 
0.30 (0.25 – 0.37) 
Reference 
p<0.0001 
0.25 (0.20 – 0.31) 
Reference 
Hormone Therapy: 
Yes 
No 
p<0.0001 
1.55 (1.31 – 1.83) 
Reference 
p<0.0001 
1.48 (1.24 – 1.77) 
Reference 
p=0.003 
1.34 (1.11 – 1.63) 
Reference 
95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses 
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, other types of treatment and stage at diagnosis 
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and 
health insurance 
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Table 10: Full Cox proportional hazards regression models for time to first hormone 
therapy 
Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
Appalachian Region:   
Appalachian  
Non-Appalachian 
p=0.83 
1.02 (0.87 – 1.20) 
Reference 
p=0.75 
0.97 (0.83 – 1.15) 
Reference 
p=0.50 
1.07 (0.89 – 1.28) 
Reference 
Age at Diagnosis: p<0.0001 
1.02 (1.01 – 1.03) 
p=0.55 
1.002 (0.99–1.01) 
p=0.16 
1.01 (0.997–1.02) 
Stage at Diagnosis: 
Stage 0 
Stage 1 
Stage 2 and Stage 3 
Stage 4  
p<0.0001 
0.65 (0.37 – 1.17) 
0.67 (0.44 – 1.03) 
0.38 (0.25 – 0.59) 
Reference 
p=0.0002 
0.30 (0.17 – 0.55) 
0.49 (0.31 – 0.78) 
0.42 (0.26 – 0.67) 
Reference 
p=0.01 
0.38 (0.19–0.75) 
0.54 (0.32 – 0.89) 
0.46 (0.28 – 0.78) 
Reference 
Monthly Income: 
<$1,000 
$1,000 - $1,999 
$2,000 – 2,999 
$3,000 - $3,999 
$4,000 - $4,999 
≥$5,000 
p=0.16 
Reference 
1.44 (1.05 – 1.98) 
1.54 (1.11 – 2.15) 
1.29 (0.93 – 1.81) 
1.43 (1.01 – 2.01) 
1.44 (1.07– 1.93) 
 
p=0.01 
Reference 
1.61 (1.15 – 2.25) 
1.24 (0.86 – 1.79) 
1.27 (0.88 – 1.82) 
1.65 (1.14 – 2.40) 
1.59 (1.14 – 2.21) 
Health Insurance: 
Uninsured 
Medicaid 
Medicare 
Private insurance 
p=0.51 
1.09 (0.65 – 1.83) 
0.81 (0.61 – 1.08) 
0.99 (0.84 – 1.17) 
Reference 
 
p=0.0009 
0.83 (0.45 – 1.54) 
0.84 (0.59 – 1.19) 
0.64 (0.51 – 0.79) 
Reference 
Surgery: 
Yes 
p=0.001 
0.33 (0.17 – 0.64) 
p=0.0008 
0.30 (0.15 – 0.61) 
p=0.002 
0.29 (0.13 – 0.62) 
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Predictor Unadjusted HR 
 (95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR** 
 (95% CI)  
No Reference Reference Reference 
Radiation: 
Yes 
No 
p=0.86 
1.01 (0.88 – 1.17) 
Reference 
p=0.55 
1.05 (0.90 – 1.21) 
Reference 
p=0.59 
0.96 (0.81 – 1.13) 
Reference 
Chemotherapy: 
Yes 
No 
p<0.0001 
0.33 (0.28 – 0.38) 
Reference 
p<0.0001 
0.30 (0.15 – 0.61) 
Reference 
p<0.0001 
0.27 (0.22 – 0.34) 
Reference 
95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses 
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, other types of treatment and stage at diagnosis 
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at 
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and 
health insurance 
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Table 11: Spearman Correlation Coefficients 
Variables Appalachian 
Region 
Education 
Attainment 
Monthly 
Income 
Private 
Insurance 
Medicaid Medicare 
Appalachian 
Region  
1 -0.18 -0.19 -0.15 0.06 0.09 
 p<.0001 p<.0001 p<.0001 p=0.03 p=0.001 
Education 
Attainment 
-0.18 1 0.49 0.31 -0.14 -0.22 
p<.0001  p<.0001 p<.0001 p<.0001 p<.0001 
Monthly 
Income 
-0.19 0.49 1 0.41 -0.28 -0.22 
p<.0001 p<.0001  p<.0001 p<.0001 p<.0001 
Private 
insurance 
-0.15 0.31 0.41 1 -0.39 -0.78 
p<.0001 p<.0001 p<.0001  p<.0001 p<.0001 
Medicaid 0.06 -0.14 -0.28 -0.39 1 -0.17 
p=0.03 p<.0001 p<.0001 p<.0001  p<.0001 
Medicare 0.09 -0.22 -0.22 -0.78 -0.17 1 
p=0.001 p<.0001 p<.0001 p<.0001 p<.0001  
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Table 12: Variance Inflation  
Dependent Variable: Number of Days between Diagnosis Date and First Treatment 
Variable  DF Parameter Estimate Standard Error t Value p value| Variance Inflation 
Intercept 1 22.03 2.40 9.19 <.0001 0 
Appalachian Region 1 -2.59 1.36 -1.91 0.06 1.06 
Education Attainment 1 0.34 0.50 0.68 0.49 1.34 
Monthly Income 1 -0.18 0.41 -0.44 0.66 1.47 
Health Insurance  1 0.22 0.89 0.25 0.80 1.25 
 
